Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 2065 - 2072 of 12086 results

Providing Critical Support to a Community Lifeline
December 1, 2022| Article| Viewpoint

FINRA to Examine Broker-Dealer Crypto Communications
December 1, 2022| Blog| Viewpoint

With House In flux, Public Finance Advocates Stay The Course
December 1, 2022| News

SEC Adopts New Incentive-Based Compensation "Clawback" Rule
November 30, 2022| Blog| Viewpoint

ERISA Fiduciaries May Consider ESG Factors in Selecting Investments and Exercising Shareholder Rights
November 30, 2022| Alert| Viewpoint

New Year, New Laws: Changes to New York Health Care Provider Staffing Laws Taking Effect in January 2023
November 30, 2022| Blog| Viewpoint

From the Edge - In the Boardroom: Special Edition - Lessons from Theranos
November 29, 2022| Podcast| Viewpoint

Mintz Lands New Chair for Sports and Entertainment Practice
November 29, 2022| News
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
